Johnson & Johnson’s stock rose 1.5% in premarket trade Tuesday, after the medtech and drug company posted better-than-expected third-quarter earnings and raised its profit guidance.
Sales rose 6.8% to $21.351 billion from $19.996 billion a year ago, also ahead of the $21.036 billion FactSet consensus. The company spun off its consumer health business earlier this year into a separate company called Kenvue KVUE, +0.88%. Kenvue houses the company’ consumer health business which includes a host of household name brands, including Tylenol, Listerine, Band-Aid, Neutrogena and Nicorette.
It expects full-year EPS to range from $10.02 to $10.08, compared with prior guidance of $9.90 to $10.00. The company expects adjusted EPS to range from $10.07 to $10.13, compared with prior guidance of $10.00 to $10.10.
대한민국 최근 뉴스, 대한민국 헤드 라인
Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.
출처: MarketWatch - 🏆 3. / 97 더 많은 것을 읽으십시오 »
출처: MarketWatch - 🏆 3. / 97 더 많은 것을 읽으십시오 »
출처: NBCLA - 🏆 319. / 59 더 많은 것을 읽으십시오 »
출처: NBCNewYork - 🏆 270. / 63 더 많은 것을 읽으십시오 »
출처: Investingcom - 🏆 450. / 53 더 많은 것을 읽으십시오 »